TriangleNCT01438177 · OUTCOME
Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- until clinical response (up to 2 years)
Analysis population: Study was terminated prior to collection of this data point.
Groups in this outcome
Velcade+Cyclophosphamide+Chloroquine
VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32. Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35. Chloroquine given at 500 mg orally daily on days 1-14 and 22-35. Each cycle is 42 days in length.
| Group | Source count |
|---|---|
| Velcade+Cyclophosphamide+Chloroquine | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- groups
- description
- VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32. Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35. Chloroquine given at 500 mg orally daily on days 1-14 and 22-35. Each cycle is 42 days in length.
- id
- OG000
- title
- Velcade+Cyclophosphamide+Chloroquine
- population Description
- Study was terminated prior to collection of this data point.
- reporting Status
- POSTED
- time Frame
- until clinical response (up to 2 years)
- title
- Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice